Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study.
- DOI
- 10.1177/17562848251410771
- Published
- 2026
- Container
- Therapeutic advances in gastroenterology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/17562848251410771,
title = {Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study.},
author = {Narita Y and Kumanishi R and Takahashi K and Masuishi T and Taniguchi H and Kadowaki S and Honda K and Ando M and Fukui T and Tajika M and Muro K},
year = {2026},
journal = {Therapeutic advances in gastroenterology},
doi = {10.1177/17562848251410771},
url = {https://doi.org/10.1177/17562848251410771}
}RIS
TY - JOUR TI - Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study. AU - Narita Y AU - Kumanishi R AU - Takahashi K AU - Masuishi T AU - Taniguchi H AU - Kadowaki S AU - Honda K AU - Ando M AU - Fukui T AU - Tajika M AU - Muro K PY - 2026 JO - Therapeutic advances in gastroenterology DO - 10.1177/17562848251410771 UR - https://doi.org/10.1177/17562848251410771 ER -
APA
Y, N., R, K., K, T., T, M., H, T., S, K., K, H., M, A., T, F., M, T., & K, M. (2026). Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study.. Therapeutic advances in gastroenterology. https://doi.org/10.1177/17562848251410771
Source records
- pubmed · retrieved 2026-09-27T10:13:51.291Z